首页 > 市场调查报告书 > 消费品

健康美容化妆品

市场调查报告书

商品编码

1588567

全球长寿治疗市场 - 2024-2031

Global Longevity Therapeutics Market - 2024-2031

出版日期: 2024年11月08日 | 出版商:

DataM Intelligence | 英文 183 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

简介目录

概述

2023年，全球长寿治疗市场规模达316.7亿美元，预计2031年将达到520.3亿美元，2024-2031年预测期间复合年增长率为6.4%。

长寿疗法，也称为长寿医学或抗衰老医学，是一个快速发展的领域，专注于帮助人们活得更长，过上更健康的生活。它采用多方面的方法，整合多种策略来解决老化的基本过程。

长寿治疗方法包括标靶药物治疗、基因为基础的干预措施、再生医学技术、营养补充剂和生活方式改变，所有这些都旨在减轻衰老的不利影响并促进健康长寿。该市场包括各种治疗类别，包括药物治疗、基因疗法、细胞疗法和生活方式改变，所有这些都旨在解决衰老过程的不同方面。

市场动态：

司机

慢性病盛行率上升和人口老化

全球长寿治疗市场的需求是由多种因素所驱动的。与老化相关的慢性疾病（包括心血管疾病、神经退化性疾病、癌症和代谢紊乱）的盛行率不断增加，是推动长寿治疗市场成长的主要因素。随着全球人口持续老化，这些与年龄相关的疾病的发生率增加。

根据世界卫生组织 2022 年 10 月的资料，65 岁及以上人口的增加预计到2050 年将翻一番，达到约15 亿，人口老龄化和与年龄相关的疾病数量的增加将推动对医疗设备的需求。老年人口对预防性医疗保健重要性的认识不断增强，这将推动对补充剂、药物和生活方式改变的需求，以延长寿命和预防与年龄相关的疾病。

此外，行业研究活动的主要参与者和个人意识的提高正在推动长寿治疗市场的成长。例如，2024 年2 月，西北大学范伯格医学院的波托茨纳克长寿研究所启动了人类长寿实验室，这是一项重要的纵向和横断面研究，旨在研究实际年龄（一个人的实际寿命）之间的联繫）和生物年龄。这项研究旨在了解这两种形式的老化在不同器官系统中如何相互关联，并旨在验证可能减缓或逆转老化过程的干预措施。

此外，在 2024 年 9 月的长寿科技新闻中，组合生物製剂正在成为一种有前途的长寿治疗策略，特别是在与年龄相关的疾病方面。这种方法涉及使用多种生物製剂同时针对不同的途径，有可能提高治疗效果并解决老化的复杂本质。

同样，2024 年 2 月，ADvantage Therapeutics 宣布任命 Makoto Kuro-o 教授为其科学顾问委员会成员，表彰他对衰老研究的先进贡献，特别是发现与衰老和健康相关的 Klotho 基因。这项策略补充旨在加强公司对开发神经退化性疾病疗法的关注。

限制

监管挑战、伦理考量和有限的临床证据等因素预计将阻碍市场的发展。

The longevity therapeutics approach encompasses targeted drug therapies, gene-based interventions, regenerative medicine techniques, nutritional supplements, and lifestyle modifications, all of which are aimed at mitigating the detrimental effects of aging and promoting healthy longevity. The market includes various therapeutic categories, including pharmacological treatments, gene therapies, cell therapies, and lifestyle changes, all aimed at addressing different facets of the aging process.

Market Dynamics: Drivers

Rising prevalence of chronic diseases and the aging population

The demand for the global longevity therapeutics market is driven by multiple factors. The increasing prevalence of chronic diseases linked to aging, including cardiovascular diseases, neurodegenerative disorders, cancer, and metabolic disorders, is a major factor propelling the growth of the longevity therapeutics market. As the global population continues to age, the occurrence of these age-related conditions rises.

As per WHO data in October 2022, the increase in the number of individuals aged 65 and older, which is expected to double by 2050 to around 1.5 billion, the rising number of aging population and age-related diseases that would propel will the demand for the longevity therapeutics market. The growing awareness among the aging population regarding the significance of preventive healthcare will drive the demand for supplements, medications, and lifestyle changes designed to enhance longevity and avert age-related illnesses.

Moreover, key players in the industry research activities and developing awareness among individuals, are driving longevity therapeutics market growth. For instance, in February 2024, The Potocsnak Longevity Institute at Northwestern University Feinberg School of Medicine launched the Human Longevity Laboratory, an important longitudinal and cross-sectional study aimed at examining the connection between chronological age (the actual number of years a person has lived) and biological age. This research seeks to understand how these two forms of aging relate to one another across various organ systems and aims to validate interventions that could potentially slow down or reverse the aging process.

Also, in Longevity Technology news in September 2024, combination biologics are emerging as a promising strategy for longevity therapy, particularly in age-related diseases. This approach involves using multiple biological agents that target different pathways simultaneously, potentially enhancing therapeutic efficacy and addressing the complex nature of aging.

Similarly, in February 2024, ADvantage Therapeutics announced the appointment of Professor Makoto Kuro-o to its Scientific Advisory Board, recognizing his advanced contributions to aging research, particularly for discovering the Klotho gene associated with longevity and health in aging. This strategic addition aims to enhance the company's focus on developing therapies for neurodegenerative diseases.

Restraints

Factors such as regulatory challenges, ethical considerations, and limited clinical evidence, are expected to hamper the market.

Segment Analysis

The global longevity therapeutics market is segmented based on product type, application, distribution channels, and region.

The dietary supplements segment accounted for approximately 76.3% of the global longevity therapeutics market share

The dietary supplements segment is expected to hold the largest market share over the forecast period. This segment includes a variety of formulations designed to promote health and longevity. This segment primarily features two categories: nutraceuticals and vitamins and minerals, both of which play crucial roles in enhancing overall health and preventing age-related diseases.

Nutraceuticals, natural compounds extracted from food sources, are crucial players in the longevity therapeutics market. These substances offer health advantages beyond basic nutrition, making them increasingly attractive to consumers who want to extend their health span and reduce the risk of age-related illnesses. Resveratrol, nicotinamide mononucleotide (NMN), and coenzyme Q10 (CoQ10) are key examples of these nutraceuticals.

Nicotinamide mononucleotide (NMN) plays a pivotal role in the longevity market as a supplement aimed at enhancing health and mitigating age-related decline. NMN is a precursor to nicotinamide adenine dinucleotide (NAD+), a crucial molecule involved in energy metabolism, DNA repair, and various cellular processes. As individuals age, NAD+ levels naturally decline, which can negatively affect cellular function and contribute to the onset of age-related conditions such as neurodegenerative diseases, metabolic disorders, and decreased energy levels.

Moreover, key players in the industry launching innovative products that would drive this segment's growth in the longevity therapeutics market. For instance, Decode Age introduced the MAG7, (Seven Complex Magnesium), and Coenzyme Q10 (Ubiquinol).

Decode Age, a pioneering health and wellness brand in India, has launched "Decode Blood Age," the country's first blood-based biological age test. This innovative approach aims to provide individuals with insights into their true health status by analyzing specific biomarkers derived from blood samples. Unlike chronological age, which simply reflects the number of years a person has lived, biological age reveals the rate at which an individual's body is aging on a cellular level.

Also, Zeropharm introduced clinically validated NMN 250 MG + Berberine Capsules, each containing 250 mg of high-purity NMN and powerful Berberine. These capsules are formulated to enhance NAD+ levels, boost energy, improve focus, support cellular health, promote heart health, and contribute to long-term longevity. For optimal results, take one capsule daily after your morning meal. Experience increased vitality and overall well-being.

Similarly, TeloX is an innovative, plant-derived supplement that combines a potent blend of therapeutic polyphenols naturally extracted from olive leaf, grapevine, and Superoxide Dismutase (SOD). These phytochemical compounds possess powerful antioxidant properties that neutralize harmful free radicals and provide essential nutrients to support mitochondrial function and promote cellular longevity.

Geographical Analysis

North America accounted for approximately 43.6% of the global longevity therapeutics market share

North America region is expected to hold the largest market share over the forecast period owing to the rising geriatric population and age-related diseases that would drive this market growth. Moreover, growing health consciousness, developments in biomedical research, and increased investment in longevity research and technological advancements would increase longevity therapeutics market growth in this region.

In addition, a major number of key players' presence, strategies such as partnerships & collaborations, and key developments would drive longevity therapeutics market growth. For instance, in April 2024, researchers at the Children's Hospital of Philadelphia (CHOP) and Stanford Medicine identified the FOXO1 protein as a critical factor in enhancing the longevity and effectiveness of CAR-T cells, which are engineered immune cells used in cancer treatment. This discovery is significant because the success of CAR-T cell therapy hinges on the ability of these cells to survive long enough in the body to effectively combat cancer.

Similarly, in California, in June 2024, Alamar Biosciences, a company focused on precision proteomics for early disease detection, announced the launch of the next phase of the Biomarkers of Aging Challenge Series in collaboration with the Biomarkers of Aging Consortium. This initiative aims to tackle one of the most pressing issues in the field of longevity, the need for reliable biomarkers that accurately reflect biological age.

Market Segmentation

By Product Type

Dietary Supplements
- NMN (Nicotinamide Mononucleotide)
- PQQ (Pyrroloquinoline quinone)
- Apigenin
- L-Tryptophan
- Others
Others

By Application

Senescence Inhibition
Cardiovascular Diseases
Cancer
Others

By Distribution Channel

Pharmacies
Online
Retail Stores

By Region

North America
- U.S.
- Canada
- Mexico
Europe
- Germany
- U.K.
- France
- Spain
- Italy
- Rest of Europe
South America
- Brazil
- Argentina
- The rest of South America
Asia-Pacific
- China
- India
- Japan
- South Korea
- Rest of Asia-Pacific
Middle East and Africa

Competitive Landscape

The major global players in the longevity therapeutics market include Decode Age, Zeroharm, Gataca, Longevity By Nature, ProHealth, Inc., Xandro Lab., NanoSPACE, AgeX Therapeutics, Inc., T.A. SCIENCES, and Elysium Health, Inc. among others.

Key Developments

In September 2024, the Estate, introduced a luxury hospitality concept, has emerged from a collaboration between lifestyle company SBE, its visionary founder Sam Nazarian, and renowned entrepreneur Tony Robbins. This innovative venture seamlessly blends high-end accommodations with cutting-edge health and wellness services, catering to the increasing demand for longevity and disease prevention solutions.
In April 2024, the Longevity India Initiative, spearheaded by the Indian Institute of Science (IISc), embarks on a mission to propel research on aging and promote extended healthy lifespans in India. This far-reaching endeavor tackles the complex challenges of aging through a holistic, multidisciplinary approach that seamlessly blends expertise from the realms of biology, technology, and healthcare.

Why Purchase the Report?

To visualize the global longevity therapeutics market segmentation based on product type, application, distribution channels, and region and understand key commercial assets and players.
Identify commercial opportunities by analyzing trends and co-development.
Excel data sheet with numerous data points of the longevity therapeutics market with all segments.
PDF report consists of a comprehensive analysis after exhaustive qualitative interviews and an in-depth study.
Product mapping is available in excel consisting of key products of all the major players.

The global longevity therapeutics market report would provide approximately 62 tables, 52 figures, and 183 pages.

Target Audience 2023

Manufacturers/ Buyers
Industry Investors/Investment Bankers
Research Professionals
Emerging Companies

1. Methodology and Scope

1.1. Research Methodology
1.2. Research Objective and Scope of the Report

2. Definition and Overview

3. Executive Summary

3.1. Snippet by Product Type
3.2. Snippet by Application
3.3. Snippet by Distribution Channels
3.4. Snippet by Region

4. Dynamics

4.1. Impacting Factors
- 4.1.1. Drivers
  - 4.1.1.1. Rising Prevalence of Chronic Diseases and Aging Population
- 4.1.2. Restraints
  - 4.1.2.1. Regulatory Challenges
- 4.1.3. Opportunity
- 4.1.4. Impact Analysis

5. Industry Analysis

5.1. Porter's Five Force Analysis
5.2. Supply Chain Analysis
5.3. Pricing Analysis
5.4. Regulatory Analysis

6. By Product Type

6.1. Introduction
- 6.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
- 6.1.2. Market Attractiveness Index, By Product Type
6.2. Dietary Supplements *
- 6.2.1. Introduction
- 6.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
- 6.2.3. NMN (Nicotinamide Mononucleotide)
- 6.2.4. PQQ (Pyrroloquinoline quinone)
- 6.2.5. Apigenin
- 6.2.6. L-Tryptophan
- 6.2.7. Others
6.3. Others

7. By Application

7.1. Introduction
- 7.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
- 7.1.2. Market Attractiveness Index, By Application
7.2. Senescence Inhibition*
- 7.2.1. Introduction
- 7.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
7.3. Cardiovascular Diseases
7.4. Cancer
7.5. Others

8. By Distribution Channels

8.1. Introduction
- 8.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channels
- 8.1.2. Market Attractiveness Index, By Distribution Channels
8.2. Pharmacies *
- 8.2.1. Introduction
- 8.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
8.3. Online
8.4. Retail Stores

9. By Region

9.1. Introduction
- 9.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region
- 9.1.2. Market Attractiveness Index, By Region
9.2. North America
- 9.2.1. Introduction
- 9.2.2. Key Region-Specific Dynamics
- 9.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
- 9.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
- 9.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channels
- 9.2.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
  - 9.2.6.1. U.S.
  - 9.2.6.2. Canada
  - 9.2.6.3. Mexico
9.3. Europe
- 9.3.1. Introduction
- 9.3.2. Key Region-Specific Dynamics
- 9.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
- 9.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
- 9.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channels
- 9.3.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
  - 9.3.6.1. Germany
  - 9.3.6.2. U.K.
  - 9.3.6.3. France
  - 9.3.6.4. Spain
  - 9.3.6.5. Italy
  - 9.3.6.6. Rest of Europe
9.4. South America
- 9.4.1. Introduction
- 9.4.2. Key Region-Specific Dynamics
- 9.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
- 9.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
- 9.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channels
- 9.4.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
  - 9.4.6.1. Brazil
  - 9.4.6.2. Argentina
  - 9.4.6.3. Rest of South America
9.5. Asia-Pacific
- 9.5.1. Introduction
- 9.5.2. Key Region-Specific Dynamics
- 9.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
- 9.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
- 9.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channels
- 9.5.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
  - 9.5.6.1. China
  - 9.5.6.2. India
  - 9.5.6.3. Japan
  - 9.5.6.4. South Korea
  - 9.5.6.5. Rest of Asia-Pacific
9.6. Middle East and Africa
- 9.6.1. Introduction
- 9.6.2. Key Region-Specific Dynamics
- 9.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
- 9.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
- 9.6.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channels

10. Competitive Landscape

10.1. Competitive Scenario
10.2. Market Positioning/Share Analysis
10.3. Mergers and Acquisitions Analysis

11. Company Profiles

11.1. Decode Age*
- 11.1.1. Company Overview
- 11.1.2. Product Portfolio and Description
- 11.1.3. Financial Overview
- 11.1.4. Key Developments
11.2. Zeroharm
11.3. Gataca
11.4. Longevity By Nature
11.5. ProHealth, Inc.
11.6. Xandro Lab.
11.7. NanoSPACE
11.8. AgeX Therapeutics, Inc.
11.9. T.A. SCIENCES
11.10. Elysium Health, Inc.

LIST NOT EXHAUSTIVE